DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Centanafadine is an investigational drug.
There have been 8 clinical trials for Centanafadine. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2018.
The most common disease conditions in clinical trials are Hyperkinesis, Attention Deficit Disorder with Hyperactivity, and Disease. The leading clinical trial sponsors are Otsuka Pharmaceutical Development & Commercialization, Inc., Neurovance, Inc., and [disabled in preview].
There are fifteen US patents protecting this investigational drug and seventy-nine international patents.
Recent Clinical Trials for Centanafadine
|A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.||Phase 1|
|A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.||Phase 1|
|Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.||Phase 2|
Top disease conditions for Centanafadine
Top clinical trial sponsors for Centanafadine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Centanafadine||Get Started Free||1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders||OTSUKA AMERICA PHARMACEUTICAL, INC. (Rockville, MD)||Get Started Free|
|Centanafadine||Get Started Free||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||Get Started Free|
|Centanafadine||Get Started Free||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Centanafadine||Australia||AU2006275870||2025-07-27||Get Started Free|
|Centanafadine||Brazil||BRPI0613943||2025-07-27||Get Started Free|
|Centanafadine||Canada||CA2659215||2025-07-27||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|